Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Academic Article uri icon

Overview

MeSH

  • Acute Disease
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Monitoring, Physiologic
  • Prognosis
  • Sialic Acid Binding Ig-like Lectin 3
  • Survival Rate

MeSH Major

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Immunotoxins
  • Leukemia, Myeloid
  • Neoplasm Recurrence, Local

abstract

  • We analyzed the safety and efficacy of Mylotarg (gemtuzumab ozogamicin, an antibody-targeted chemotherapy consisting of a humanized anti-CD33 antibody linked to calicheamicin, a potent antitumor antibiotic) in the treatment of 101 patients > or =60 years of age with acute myeloid leukemia (AML) in untreated first relapse in three open-label trials. Mylotarg is administered as a 2-h intravenous infusion at 9 mg/m(2) for two doses with 14 days between doses. The overall remission rate was 28%, with complete remission (CR) in 13% of patients and complete remission with incomplete platelet recovery (CRp) in 15%. Median survival was 5.4 months for all patients and 14.5 months and 11.8 months for patients achieving CR and CRp, respectively. CD33 antigen is present on normal hematopoietic progenitor cells; thus, an expected high incidence of grade 3 or 4 neutropenia (99%) and thrombocytopenia (99%) was observed. The incidences of grade 3 or 4 elevations of bilirubin and hepatic transaminases were 24% and 15%, respectively. There was a low incidence of grade 3 or 4 mucositis (4%) and infections (27%) and no treatment-related cardiotoxicity, cerebellar toxicity, or alopecia. Mylotarg is an effective treatment for older patients with CD33-positive AML in first relapse and has acceptable toxicity.

authors

publication date

  • September 2002

has subject area

  • Acute Disease
  • Adult
  • Aged
  • Aged, 80 and over
  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Disease-Free Survival
  • Female
  • Humans
  • Immunotoxins
  • Leukemia, Myeloid
  • Male
  • Middle Aged
  • Monitoring, Physiologic
  • Neoplasm Recurrence, Local
  • Prognosis
  • Sialic Acid Binding Ig-like Lectin 3
  • Survival Rate

Research

keywords

  • Clinical Trial
  • Clinical Trial, Phase II
  • Journal Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/sj.leu.2402677

PubMed ID

  • 12200674

Additional Document Info

start page

  • 1627

end page

  • 1636

volume

  • 16

number

  • 9